Under the terms of a license agreement for beta-sheet breaker technology, Axonyx Inc. has announced the receipt of a milestone payment of $1 million from Serono S.A. The milestone payment was triggered when Serono initiated a Phase I clinical trial with a beta-sheet breaker peptide for the potential treatment of Alzheimer’s disease. The study will Read more about Axonyx Announces Milestone Payment From Serono[…]